Clinical trials: Pleural Neoplasm
Non Small Cell Lung Cancer
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
The purpose of this clinical trial is to find out whether or not the combination of NOV-002 with chemotherapy (paclitaxel and carboplatin) is better at improving overall survival time when compared to chemotherapy alone in people…
- Trial name
- NCT00347412
- Testing
- Paclitaxel, NOV-002, Carboplatin
- Where
- 75 sites in United States, Canada and 10 more
- Volunteers
- 903 people
- Sponsor
- Cellectar Biosciences, Inc.
Advanced Solid Tumor, Advanced Cancer
AMT-151 in Patients With Selected Advanced Solid Tumours
This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-151, a novel…
- Conditions
- Advanced Solid Tumor, Advanced Cancer, Advanced Carcinoma, Ovarian Cancer
- Trial name
- NCT05498597
- Testing
- AMT-151
- Where
- 9 sites in Australia, China
- Volunteers
- 30 people
- Sponsor
- Multitude Therapeutics Inc.
Malignant Pleural Effusion, Malignant Ascites
Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites
The objective of this study is to compare the efficacy of Endostar/cisplatin with cisplatin alone or Endostar alone in patients with malignant pleural effusion or ascites.
- Trial name
- NCT01327235
- Testing
- Endostar, Cisplatin
- Where
- 3 sites in China
- Volunteers
- 336 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Pleural Effusion, Pleural Effusion, Malignant
Use of Guidance Videos to Increase Engagement and Decrease Anxiety in Patients Undergoing Pleural Tap
Patients planned to undergo a pleural tap will get verbal explanation or watch a personalized guidance video in addition to verbal explanation.
- Conditions
- Pleural Effusion, Pleural Effusion, Malignant, Pleural Pleurisy Effusion
- Trial name
- NCT04254445
- Testing
- Personalized training video
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- GistMed Ltd.
Fallopian Tube Cancer, Metastatic Cancer
ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ILX-295501 in treating patients who have stage III or…
- Conditions
- Fallopian Tube Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00005645
- Testing
- ILX-295501
- Where
- 8 sites in United States
- Sponsor
- Genzyme, a Sanofi Company
Pleural Mesothelioma, Non-small Cell Lung Cancer
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)
The Primary Objective was: -To determine the antitumor activity of SAR444245 in combination with other anticancer therapies. The Secondary Objectives were: To confirm the dose and to assess the safety profile of SAR444245 when…
- Trial name
- NCT04914897
- Testing
- THOR-707, Pembrolizumab
- Where
- 35 sites in United States, Argentina and 9 more
- Volunteers
- 106 people
- Sponsor
- Sanofi
Lung Cancer, Small Cell Lung Cancer
QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung Cancer
This trial is titled "A Phase 1b/2 trial of AMG 479 or AMG 102 with Platinum-Based Chemotherapy as First-Line Treatment for Extensive Stage Small-Cell Lung Cancer (SCLC)." Part 1, the phase 1b portion of this study, is a…
- Conditions
- Lung Cancer, Small Cell Lung Cancer, Solid Tumors, Extensive-stage Small Cell Lung Cancer
- Trial name
- SCLC (NCT00791154)
- Testing
- AMG 479, Etoposide, AMG 102
- Volunteers
- 213 people
- Sponsor
- NantCell, Inc.
Relapsed Malignant Mesothelioma
A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma
The purpose of this study is to evaluate rising dose levels of VS-5584 administered in combination with a fixed dose of VS-6063 in subjects with relapsed malignant mesothelioma to determine a recommended Phase 2 dose (RP2D) for…
- Trial name
- NCT02372227
- Testing
- VS-5584 and VS-6063
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 21 people
- Sponsor
- Verastem, Inc.
Non-Small Cell Lung Cancer
A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC
The primary objective of this study will be to determine the progression free survival of patients with stage IIIb/IV non-small cell lung cancer (NSCLC) treated with dual agent monoclonal antibody therapy consisting of cetuximab…
- Trial name
- NCT00343291
- Testing
- Cetuximab, Bevacizumab, Paclitaxel
- Where
- 43 sites in United States
- Volunteers
- 121 people
- Sponsor
- Eli Lilly and Company
Malignant Pleural Mesothelioma, Non-Small Cell Lung Cancer
A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma
This is an open-label, multicenter, phase 1/2 study of BBI608 in combination with pemetrexed and cisplatin chemotherapy as a 1st line treatment for Malignant Pleural Mesothelioma (MPM).
- Trial name
- NCT02347917
- Testing
- BBI608, Pemetrexed, Cisplatin
- Where
- 2 sites in Japan
- Volunteers
- 28 people
- Sponsor
- Sumitomo Pharma Co., Ltd.
Unresectable Pleural or Peritoneal Malignant Mesothelioma
Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma
This is a Phase 2b, randomized, double-blind, parallel-group study. Subjects with unresectable pleural or peritoneal malignant mesothelioma will be randomized in a 2:1 ratio to receive either tremelimumab or placebo.
- Trial name
- Tremelimumab (NCT01843374)
- Testing
- Tremelimumab
- Where
- 104 sites in United States, Australia and 17 more
- Volunteers
- 571 people
- Sponsor
- MedImmune LLC
Solid Tumors, Adult, Solid Tumor
Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors
This is a Phase 1, first-in-human (FIH) clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of IK-930, an oral TEAD inhibitor, administered orally…
- Conditions
- Solid Tumors, Adult, Solid Tumor, Malignant Pleural Mesothelioma (MPM), Epithelioid Hemangioendothelioma (EHE)
- Trial name
- NCT05228015
- Testing
- IK-930, Osimertinib
- Where
- 12 sites in United States, Australia and 1 more
- Volunteers
- 67 people
- Sponsor
- Ikena Oncology
Advanced Recurrent Malignant Pleural Epithelioid Mesothelioma, Advanced Recurrent Malignant Peritoneal Epithelioid Mesothelioma
First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin
The purpose of this study is to evaluate, in patients with tumors known to express the protein mesothelin, the following properties of BAY2287411 injection: safety (to identify, assess, minimize, and appropriately manage the…
- Conditions
- Advanced Recurrent Malignant Pleural Epithelioid Mesothelioma, Advanced Recurrent Malignant Peritoneal Epithelioid Mesothelioma, Advanced Recurrent Serous Ovarian Cancer, Advanced Pancreatic Ductal Adenocarcinoma (Optional, Dose Expansion, Not Initiated)
- Trial name
- NCT03507452
- Testing
- BAY2287411
- Where
- 7 sites in United States, Finland and 3 more
- Volunteers
- 36 people
- Sponsor
- Bayer
Mesothelioma, Lung Cancer
Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014)
The goal of this study is to assess the efficacy and safety of an oral investigational drug suberoylanilide hydroxamic acid (vorinostat, MK-0683) compared to placebo, in the treatment of participants with advanced malignant…
- Trial name
- NCT00128102
- Testing
- Vorinostat
- Volunteers
- 661 people
- Sponsor
- Merck Sharp & Dohme LLC
Malignant Pleural Mesothelioma
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
This study is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study of defactinib (VS-6063) in subjects with malignant pleural mesothelioma (MPM) who have not progressed (confirmed partial response or stable…
- Trial name
- COMMAND (NCT01870609)
- Testing
- defactinib (VS-6063)
- Where
- 73 sites in United States, Australia and 13 more
- Volunteers
- 344 people
- Sponsor
- Verastem, Inc.
Mesothelioma
Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients
The purpose of this study is to test the effectiveness and tolerability of the combination of Nivolumab and Ipilimumab compared to Pemetrexed and Cisplatin or Carboplatin in patients with unresectable pleural mesothelioma.
- Trial name
- CheckMate743 (NCT02899299)
- Testing
- Nivolumab, Ipilimumab, Pemetrexed
- Where
- 109 sites in United States, Australia and 19 more
- Volunteers
- 605 people
- Sponsor
- Bristol-Myers Squibb
Malignant Mesothelioma
ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether Onconase plus doxorubicin is more effective than doxorubicin alone in…
- Trial name
- NCT00003034
- Testing
- doxorubicin hydrochloride, ranpirnase
- Where
- 19 sites in United States, Germany and 2 more
- Volunteers
- 300 people
- Sponsor
- Alfacell
Advanced Cancer, Metastatic Cancer
A Study of LY3023414 in Participants With Advanced Cancer
The purpose of this study is to find a recommended dose level and schedule of dosing LY3023414 that can safely be taken by participants with advanced or metastatic cancer.
- Conditions
- Advanced Cancer, Metastatic Cancer, Non-Hodgkin's Lymphoma, Metastatic Breast Cancer
- Trial name
- NCT01655225
- Testing
- LY3023414, Midazolam, Fulvestrant
- Where
- 8 sites in United States, Italy and 1 more
- Volunteers
- 156 people
- Sponsor
- Eli Lilly and Company
Malignant Pleural Mesothelioma
An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
This research is being done to find out if pemetrexed and cisplatin work better when given together with an experimental drug called MORAb-009 in patients with malignant pleural mesothelioma.
- Trial name
- Amatuximab (NCT00738582)
- Testing
- MORAb-009 (Amatuximab), Pemetrexed, Cisplatin
- Where
- 28 sites in United States, Canada and 3 more
- Volunteers
- 89 people
- Sponsor
- Morphotek
Lung Neoplasms
GILT Docetaxel - Non-Small Cell Lung Cancer
Primary Objective: To compare response rate between genotypic groups and control group. Secondary Objective: To determine the safety, time to treatment failure and survival in control and genotypic arms.
- Trial name
- NCT00174629
- Testing
- Docetaxel/DDP, docetaxel/gemcitabine
- Where
- 3 sites in Germany, Spain and 1 more
- Volunteers
- 449 people
- Sponsor
- Sanofi